MUHA/MUSC Board of Trustees Meeting August 13, 2021 8:30 a.m - Medical University of ...

MUHA/MUSC
Board of Trustees Meeting
    August 13, 2021
        8:30 a.m.

President’s Report : FY21 Year in Review
David J. Cole, M.D., FACS
August 13, 2021

COVID-19 Response
• Key performance indicators across all MUSC Health Divisions:
      •   440,526 COVID PCR tests performed
      •   18,744 COVID antibody tests performed
      •   36,125 COVID + patients identified
      •   147,393 individuals vaccinated
      •   279,410 shots administered
      •   300+ unique testing/vaccination locations throughout the state

• The State Legislature entrusted MUSC to distribute COVID-19 tests and
   vaccines across the state ($90M, present in 46 of 46 counties).

• Stewarded $40M to MUSC Health and $19M to MUSC from the state Cares Act
   system.

• MUSC Health rolled out a paid time off (PTO) COVID-19 give back program to
   MUSC Health care team members in support of their efforts and work disruption.

• Highly successful MUSC Back2Business effort assisted 100’s of SC businesses,
   schools, municipalities, and others to safely respond to / recover from the
   pandemic.

Big Rocks
• U.S. News & World Report (USNWR) 2021-22 ranked MUSC
  Health Charleston #1 in SC, 7 years running.
   •   3 programs nationally ranked / 17 high performing specialties,
       procedures, or conditions.
   •   MUSC Health Florence ranked high performing in 4 specialties,
       procedures, or conditions.

• MUSC Shawn Jenkins Children’s Hospital ranked #1 in SC and
  tied at #12 in the Southeast per USNWR’s 2021-22 edition.

• MUSC Extramural Research dollars:
   •   $327M for FY21 compared to $271 million in FY20.
   •   In FY20, MUSC led the state in NIH funding, with more than
       $129.9 million. On track for more than $222 in FY21.
   •   Finalized, audited numbers available in October

Big Rocks – Continued
• Construction has begun on the new College of Pharmacy
  and Education space ($53M, 40,000 sq. ft).

• The enterprise wide MUSC Office of Equity launched in
  October 2020.
   • Charged with full integration of academic and health care
     delivery mission of our ongoing institutional diversity, equity,
     and inclusion work.
   • Willette Burnham-Williams, Ph.D., was named Interim Chief
     Equity Officer.
   • Hired MUSC’s first director of LGBTQ+ Health Services and
     Enterprise Resources, Chase Glenn.

• MUSC Health broke ground on the hospital to replace
  Williamsburg/Lake City Hospitals.
   • Projected opening in early 2023 as part of the MUSC Health
     Florence Division.

Big Rocks – Continued
• MUSC Health formalized a partnership with Tidelands Health,
  deepening a pre-existing clinical affiliation.
   • Enables greater access to specialty services along the coast from
     Georgetown to the NC state line.
   • Facilitates academic and research opportunities within the region.

• MUSC Health formalized a partnership with Encompass Health to
  add inpatient rehabilitation services to the Charleston Division.
   • This joint venture fills a care continuum void in the Charleston market.
   • It creates academic rotation and telehealth opportunities within all 7
     Encompass Health hospitals in SC.

• MUSC Health executed an inter-agency agreement with SC
  Department of Corrections to provide acute care services at MUSC
  Health Chester Medical Center.
   • Additional statements of work are expected to support the
     Department’s pharmacy and behavior health needs.

Big Rocks – Continued
• MUSC-P opened new ambulatory care platforms:
   • Chuck Dawley Medical Park
      •   Ambulatory surgery center, diagnostic imaging, PT/OT, and clinics
      •   Services include orthopedics, PM&R, pain management, hand
          surgery, and ophthalmology.
   • MUSC Health Nexton Medical Park
      •   Cardiology, GI surgery, infectious disease, neurology, nephrology,
          and rheumatology
   • MUSC Health Evelyn Trammell Institute for Voice and Swallowing
     at MUSC Health East
      •   First and only center in SC to provide comprehensive evaluation and
          management of voice, airway, and swallowing concerns for both
          adults and children.
   • MUSC Health Center Space
      •   Provides novel therapeutic treatment for anxiety, depression, PTSD,
          and trauma through its innovative use of Ketamine.

Innovation is what we do to achieve our vision.

Impact means our actions produce significant positive outcomes.

     Influence is derived from positive impact and enables us
         to lead health innovation for the lives we touch.

Innovation
• Guardian Needle received FDA approval, in-market this October
   •   MUSC innovators Jonathan Edwards, M.D., and Jessica Barley, Ph.D.
   •   Product prevents needle-stick injuries during intraoperative monitoring.
   •   Sold by RhythmLink ® International, LLC.

• BabySTRONG received FDA Breakthrough Device Designation
   •   MUSC innovators Doe Jenkins, M.D., Bashar Badran, Ph.D., and Mark
       George, M.D.
   •   Neonatal feeding aid for premature and at-risk infants who present with
       feeding issues.

• MUSC’s partnership with Synaptive enabled MUSC Shawn Jenkins
  Children’s Hospital to become the first pediatric hospital in North America
  to deploy Modus V 3D robotic digital microscopes in clinical setting.

• The MUSC COVID-19 Antibody Test developed by the Center for Cellular
  Therapy (>19,000 tests performed in NC and SC) will be offered in India in
  partnership with DNA Xperts.

Impact
• David Koch, M.D., MSCR, and Jared White, M.D., performed the first
  liver transplant in South Carolina for a patient with
  cholangiocarcinoma.

• MUSC Health was the highest volume CT surgery program in the
  state of South Carolina this past year
   •   MUSC Structural Heart Program also performed the 1,000th TAVR
       this year.

• The Center for International Blood and Marrow Transplant Research
  recognized the MUSC Health Blood and Marrow Transplant (BMT)
  Program as among the top 10% of transplant centers in the nation.
   •   Exceeded predicted survival rates and one of only six that have
       achieved such excellence as a combined adult and pediatric
       program.
   •   Michelle P. Hudspeth, M.D., Associate Professor of Pediatrics,
       directs the adult and pediatric BMT program.

Impact - Continued
• Led by pediatric infectious disease physician Allison Eckard,
   M.D., MUSC was first in the nation to enroll patients with multisystem
   inflammatory syndrome (MIS-C), a rare but life-threatening
   complication of COVID-19, in remestemcel-L trial.

• Public Safety Officer Lt. Patrick Kelly received the Life Saving Award for
   preventing two individual suicide attempts in March and June 2021.

• FDA granted Rare Pediatric Disease Designation to Innova
   Therapeutics IVT-8086 for the treatment of osteosarcoma.
    •   First FDA-approved therapy for individuals with osteosarcoma in 30
        years.
    •   Nancy Klauber-DeMore, M.D., is the inventor, co-founder, and clinical
        and scientific consultant for Innova Therapeutics, Inc.

Influence
• Kathleen Brady, M.D., Ph.D., Vice President for Research, received the
   Julius Axelrod Mentorship Award from the American College of
   Neuropsychopharmacology for her outstanding contribution to
   neuropsychopharmacology by mentoring and developing young scientists
   into leaders in the field.

• Dean Kilpatrick, Ph.D., COM Professor of Psychiatry, and director of the
   MUSC National Crime Victims Center, was awarded the “Visionary Voice”
   award from End Violence Against Women International.

• Hermes Florez, M.D., Ph.D., MPH, Chair of our Department of Public Health
   Sciences, has been recognized as one of “100 Inspiring Hispanic/LatinX
   Scientists in America” in connection with National Hispanic Heritage Month.

• Prabhakar Baliga, M.D., Chair of the Department of Surgery, was elected to
   the Board of Governors for the American College of Surgeons as the
   Surgical Specialty Society Governor from the Southern Surgical Association.